TY - JOUR
T1 - Cloning, expression and purification of the human Islet Amyloid Polypeptide (hIAPP) from Escherichia coli
AU - Rodriguez Camargo, Diana C.
AU - Tripsianes, Konstantinos
AU - Kapp, Tobias G.
AU - Mendes, Joaquim
AU - Schubert, Jasmin
AU - Cordes, Burghard
AU - Reif, Bernd
N1 - Publisher Copyright:
© 2014 Elsevier Inc. All rights reserved.
PY - 2015/2
Y1 - 2015/2
N2 - Type II diabetes is characterized by deposition of the hormone human Islet Amyloid Polypeptide (hIAPP). Formation of hIAPP amyloid fibrils and aggregates is considered to be responsible for pancreatic β-cell losses. Therefore, insight into the structure of hIAPP in the solid-state and in solution is of fundamental importance in order to better understand the action of small molecules, which can potentially dissolve protein aggregates and modulate cell toxicity. So far, no procedure has been described that allows to obtain the native human IAPP peptide at high yields. We present here a cloning, expression and purification protocol that permits the production of 2.5 and 3 mg of native peptide per liter of minimal and LB medium, respectively. In the construct, hIAPP is fused to a chitin binding domain (CBD). The CBD is subsequently cleaved off making use of intein splicing reaction which yield amidation of the C-terminus. The N-terminus contains a solubilization domain which is cleaved by V8 protease, avoiding additional residues at the N-terminus. The correct formation of the disulfide bond is achieved by oxidation with H2O2.
AB - Type II diabetes is characterized by deposition of the hormone human Islet Amyloid Polypeptide (hIAPP). Formation of hIAPP amyloid fibrils and aggregates is considered to be responsible for pancreatic β-cell losses. Therefore, insight into the structure of hIAPP in the solid-state and in solution is of fundamental importance in order to better understand the action of small molecules, which can potentially dissolve protein aggregates and modulate cell toxicity. So far, no procedure has been described that allows to obtain the native human IAPP peptide at high yields. We present here a cloning, expression and purification protocol that permits the production of 2.5 and 3 mg of native peptide per liter of minimal and LB medium, respectively. In the construct, hIAPP is fused to a chitin binding domain (CBD). The CBD is subsequently cleaved off making use of intein splicing reaction which yield amidation of the C-terminus. The N-terminus contains a solubilization domain which is cleaved by V8 protease, avoiding additional residues at the N-terminus. The correct formation of the disulfide bond is achieved by oxidation with H2O2.
KW - Amyloid
KW - Diabetes
KW - Escherichia coli
KW - Nuclear magnetic resonance (NMR)
KW - Recombinant protein human Islet Amyloid Polypeptide (hIAPP)
UR - http://www.scopus.com/inward/record.url?scp=84911445923&partnerID=8YFLogxK
U2 - 10.1016/j.pep.2014.10.012
DO - 10.1016/j.pep.2014.10.012
M3 - Article
C2 - 25448593
AN - SCOPUS:84911445923
SN - 1046-5928
VL - 106
SP - 49
EP - 56
JO - Protein Expression and Purification
JF - Protein Expression and Purification
ER -